Possible pentostatin-induced symptomatic hyponatremia.
Pentostatin is an adenosine deaminase inhibitor used in the treatment of hairy cell leukemia and T-cell lymphomas. A 27-year-old man with refractory cutaneous T-cell lymphoma developed severe hyponatremia 3 days after completing his first cycle of pentostatin therapy. Shortly after hospital admission, he became disoriented and was admitted to the medical intensive care unit and treated with a combination of hypertonic saline, intravenous diuretics, and fluid restriction to reestablish normal sodium homeostasis. The mechanism by which pentostatin may have induced hyponatremia in this patient is unknown; clinical and laboratory findings represented both extrarenal sodium loss and syndrome of inappropriate antidiuretic hormone. Clinicians should be aware of the possible development of life-threatening symptomatic hyponatremia in patients receiving pentostatin.
Bruno
Jeffrey J
JJ
Division of Pharmacy, University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030-4009, USA. jjbruno@mdanderson.org
Canada
Todd W
TW
D000328:Adult; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects*; D006801:Humans; D007010:Hyponatremia / Q000139:chemically induced*; D016399:Lymphoma, T-Cell / Q000188:drug therapy; D008297:Male; D015649:Pentostatin / Q000009:adverse effects*
D000903:Antibiotics, Antineoplastic; D015649:Pentostatin